Two executive appointments at Amylin
This article was originally published in Scrip
Executive Summary
Amylin Pharmaceuticals (US) has named Dr Christian Weyer senior vice-president of R&D. During his 10-year tenure at Amylin, Dr Weyer has served in leadership roles in research, clinical and corporate development, most recently as vice-president of medical development. Dr Orville Kolterman, who was formerly senior vice-president of R&D, takes on the new role of chief medical officer.